Physician profile
Heather Dyer
NPI 1528500444
$3,899.39
in general payments reported to CMS, 2019-2025
34 companies · $18.65 in 2025
The $18.65 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $987 · 2022: $866 · 2023: $1,014 · 2024: $1,014 · 2025: $18.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.91 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $618.68 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $516.38 | 2021-2024 | Farxiga, Breztri |
| Abbvie INC. | $463.48 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.93 | 2021-2024 | |
| Amgen INC. | $146.16 | 2021-2024 | Prolia, Evenity, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $127.21 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.29 | 2021-2024 | Xifaxan, Trulance |
| Arbor Pharmaceuticals, INC. | $101.24 | 2021-2022 | |
| Glaxosmithkline, LLC. | $90.50 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $75.86 | 2023 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $75.06 | 2022-2024 | |
| Exact Sciences Corporation | $74.27 | 2023-2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $66.95 | 2023-2024 | Edarbi, Edarbi |
| Incyte Corporation | $59.73 | 2024 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $58.55 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $45.61 | 2021-2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $39.61 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.46 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $33.28 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $31.95 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.41 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $19.59 | 2022 | |
| Pfizer INC. | $19.07 | 2023 | |
| Astellas Pharma US INC | $17.65 | 2024 | Veozah |
| Tolmar, INC. | $17.18 | 2024 | |
| Eisai INC. | $15.98 | 2021 | |
| Genentech USA, INC. | $15.36 | 2021 | |
| Merck Sharp & Dohme LLC | $15.23 | 2021 | |
| Medtronic, INC. | $14.33 | 2023 | Venaseal |
| Biohaven Pharmaceutical Holding Company LTD. | $13.92 | 2022 | |
| Mylan Specialty L.P. | $13.31 | 2023 | Yupelri |
| Impel Pharmaceuticals INC. | $13.00 | 2022 | |
| Neos Therapeutics, LP | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.